Parkinsonism & related disorders · 2016
MAPT haplotype diversity in multiple system atrophy.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Labbé Catherine, Heckman Michael G, Lorenzo-Betancor Oswaldo, Murray Melissa E, Ogaki Kotaro, Soto-Ortolaza Alexandra I, Walton Ronald L, Fujioka Shinsuke, Koga Shunsuke, Uitti Ryan J, van Gerpen Jay A, Petersen Ronald C, Graff-Radford Neill R, Younkin Steven G, Boeve Bradley F, Cheshire William P, Low Phillip A, Sandroni Paola, Coon Elizabeth A, Singer Wolfgang, Wszolek Zbigniew K, Dickson Dennis W, Ross Owen A
Аннотация
INTRODUCTION: Multiple system atrophy (MSA) is a rare progressive neurodegenerative disorder. MSA was originally considered exclusively sporadic but reports of association with genes such as SNCA, COQ2 and LRRK2 have demonstrated that there is a genetic contribution to the disease. MAPT has been associated with several neurodegenerative diseases and we previously reported a protective association of the MAPT H2 haplotype with MSA in 61 pathologically confirmed cases.
METHODS: In the present study, we assessed the full MAPT haplotype diversity in MSA patients using six MAPT tagging SNPs. We genotyped a total of 127 pathologically confirmed MSA cases, 86 patients with clinically diagnosed MSA and 1312 controls.
RESULTS: We identified four significant association signals in our pathologically confirmed cases, two from the protective haplotypes H2 (MSA:16.2%,
CONTROLS: 22.7%, p = 0.024) and H1E (MSA:3.0%,
CONTROLS: 9.0%, p = 0.014), and two from the rare risk haplotypes H1x (MSA:3.7%,
CONTROLS: 1.3%, p = 0.030) and H1J (MSA:3.0%,
CONTROLS: 0.9%, p = 0.021). We evaluated the association of MSA subtypes with the common protective H2 haplotype and found a significant difference with controls for MSA patients with some degree of MSA-C (MSA-C or MSA-mixed), for whom H2 occurred in only 8.6% of patients in our pathologically confirmed series (P < 0.0001).
CONCLUSIONS: Our findings provide further evidence that MAPT variation is associated with risk of MSA. Interestingly, our results suggest a greater effect size in the MSA-C compared to MSA-P for H2. Additional genetic studies in larger pathologically confirmed MSA series and meta-analytic studies will be needed to fully assess the role of MAPT and other genes in MSA.
METHODS: In the present study, we assessed the full MAPT haplotype diversity in MSA patients using six MAPT tagging SNPs. We genotyped a total of 127 pathologically confirmed MSA cases, 86 patients with clinically diagnosed MSA and 1312 controls.
RESULTS: We identified four significant association signals in our pathologically confirmed cases, two from the protective haplotypes H2 (MSA:16.2%,
CONTROLS: 22.7%, p = 0.024) and H1E (MSA:3.0%,
CONTROLS: 9.0%, p = 0.014), and two from the rare risk haplotypes H1x (MSA:3.7%,
CONTROLS: 1.3%, p = 0.030) and H1J (MSA:3.0%,
CONTROLS: 0.9%, p = 0.021). We evaluated the association of MSA subtypes with the common protective H2 haplotype and found a significant difference with controls for MSA patients with some degree of MSA-C (MSA-C or MSA-mixed), for whom H2 occurred in only 8.6% of patients in our pathologically confirmed series (P < 0.0001).
CONCLUSIONS: Our findings provide further evidence that MAPT variation is associated with risk of MSA. Interestingly, our results suggest a greater effect size in the MSA-C compared to MSA-P for H2. Additional genetic studies in larger pathologically confirmed MSA series and meta-analytic studies will be needed to fully assess the role of MAPT and other genes in MSA.